In the last trading session, 1,393,690 shares of the Geron Corporation (NASDAQ:GERN) were traded, and its beta was 1.16. Most recently the company’s share price was $1.59, and it changed around -$0.01 or -0.01% from the last close, which brings the market valuation of the company to $506.46 Million. GERN currently trades at a discount to its 52-week high of $2.4, offering almost -50.94% off that amount. The share price’s 52-week low was $1.01, which indicates that the current value has risen by an impressive 36.48% since then. We note from Geron Corporation’s average daily trading volume that its 10-day average is 2.22 Million shares, with the 3-month average coming to 3.99 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Geron Corporation stock received a consensus recommendation rating of Buy, based on a mean score of 1.7. If we narrow it down even further, the data shows that none out of 4 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended GERN as a Hold, whereas 4 deemed it a Buy, and no one rated it as Underweight. Geron Corporation is expected to report earnings per share of -$0.08 for the current quarter.

Geron Corporation (NASDAQ:GERN): Trading Information

The consensus price target as assigned by Wall Street analysts is $3.25, which translates to bears needing to increase their stock price by 104.4% from its current value. Analyst projections state that GERN is forecast to be at a low of $3 and a high of $4. In order for the stock price to hit the forecast high, the stock would need to surge +151.57% from its current level, while the stock would need to crash 88.68% from its current level to reach the projected low.

Geron Corporation (GERN) projections and forecasts

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $40Million in revenue for the current quarter. 4 analysts expect Geron Corporation to make $40Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarters a year ago were $52Million and $43Million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -23.1%. Forecasts for the next quarter put sales growth at -7%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%. Geron Corporation earnings are expected to increase by 22.7% in 2021, but the outlook is positive 5% per year for the next five years.

Geron Corporation (NASDAQ:GERN)’s Biggest Investors

Upon looking at major shareholders, it appears that insiders hold 0.17% of Geron Corporation shares, and 55.83% of them are in the hands of institutional investors. The stock currently has a share float of 55.93%. Geron Corporation stock is held by 205 institutions, with RA Capital Management, L.P. being the largest institutional investor. By Dec 30, 2020, it held 9.46% of the shares, which is about 30.13 Million shares worth $47.9 Million.

Blackrock Inc., with 7.86% or 25.02 Million shares worth $39.79 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Dec 30, 2020. The former held 8900597 shares worth $14.15 Million, making up 2.79% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 8.67 Million shares worth around $15.51 Million, which represents about 2.72% of the total shares outstanding.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free


Please enter your comment!
Please enter your name here